Likewise, increased serum levels of inflammasome-related and neuroinflammatory components, such as NLRP3, NF-κB, and caspase-1 have been found in patients with MS, a chronic inflammatory disease, during early stages of pathology [93], while inhibiting inflammasome signaling showed protective effects in animal model of MS [94]. This evidence concerns the gene NLRP3 and myeloid sarcoma.